InSite Vision Announces Positive Phase 1/2 Results For ISV-303 For The Reduction Of Pain And Inflammation After Cataract Surgery
InSite Vision Incorporated (OTCBB:INSV) announced top-line results from its recently completed Phase 1/2 clinical trial of ISV-303, a topical anti-inflammatory product intended to reduce the pain and inflammation associated with ocular surgery...